B Cell Repertoire in Determining Responses to Checkpoint Blockade in NSCLC

Immune-related adverse events following checkpoint blockade are the achilles heel of this revolutionary treatment paradigm in cancer. This poses not only a significant healthcare burden in terms of increased morbidity and mortality to our patients, but also a huge financial and socioeconomic burden. Elucidating the mechanisms underpinning this phenomenon is of key importance to be able to stratify patients at risk of toxicity and improve long-term treatment outcomes.

Key learning objectives

• Discover the mechanisms of immunotherapy
• Understand the burden and incidence of immune-related adverse events
• Review biological mechanisms
• Explore biomarker research

Who should attend?

• Researchers, post-docs, scientists, and professors in academia and pharmaceuticals working in the fields of biomarker discovery
• Those working in patient stratification, therapeutic response prediction and diagnostics, and CDx development for immuno-oncology, autoimmune and neurological diseases

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.